Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Longitudinal Metabolite Levels in Patients Receiving Maintenance PARP Inhibitors

This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.

PRIMARY OBJECTIVE:

I. To determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived cancer support factors in patients with cancer.

OUTLINE:

Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.

Inclusion Criteria:

• Adults
• Patients with ovarian cancer starting PARP inhibitor treatment

Exclusion Criteria:

• Patients unwilling to return for blood draws, patients unwilling to continue PARP inhibitor treatment for at least one month